ClinicalTrials.gg

Program

osimertinib

Also written as “Osimertinib”, “AZD9291” and “AZD9291 tablet dosing”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Neoplasms · Renal Insufficiency · Carcinoma, led by 3 companies.

Furthest: phase 4, since Feb 20, 201942 company-led studies, 15 open or runningNext primary completion: Feb 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca3914 open or runningphase 4since Feb 20, 2019Feb 25, 2013Feb 22, 2027phase 3 · NCT05629234
Eli Lilly21 open or runningphase 3since Apr 3, 2015Apr 3, 2015none ahead
Novartis10 open or runningphase 3since Mar 22, 2021Mar 22, 2021none ahead

Also a collaborator on its studies: parexel, tigermed and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Feb 25, 2013.

  1. Apr 29, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT03944772 · 247 enrolled · United States, Denmark, Italy and more
  2. Apr 1, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT04351555 · 358 enrolled · United States, Austria, Brazil and more
  3. Sep 1, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT04606771 · 30 enrolled · United States, Argentina, India and more
  4. Feb 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT04765059 · 98 enrolled · United States, China, Germany and more
  5. Mar 22, 2021Novartis's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to NovartisNovartis · NCT04816214 · 6 enrolled · Japan, Korea, Republic of, Singapore
  6. Nov 3, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05120349 · 390 enrolled · United States, Argentina, Brazil and more
  7. Nov 15, 2021Phase 2 study in Lung NeoplasmsAstraZeneca · NCT05215951 · 4 enrolled · China
  8. Mar 11, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05546866 · 51 enrolled · China
  9. Sep 1, 2022Phase 2 study in Stage II-IIIB Non-small Cell Lung CarcinomaAstraZeneca · NCT05526755 · 188 enrolled · United States, Hong Kong, Italy and more
  10. Nov 17, 2022Phase 3 study in NeoplasmsAstraZeneca · NCT05629234 · 37 enrolled · China, France, Japan and more
  11. Mar 24, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more
  12. Dec 20, 2023Phase 2 study in Lung NeoplasmsAstraZeneca · NCT06194448 · 76 enrolled · United States, China, Israel and more
  13. Nov 24, 2025Phase 2 study in Lung NeoplasmsAstraZeneca · NCT07295821 · 60 planned · China
  14. Oct 15, 2026Primary completion moved from 2026-09-30 to 2027-01-11Date moved laterphase 3 · +3 months · NCT06417814

Ahead

  1. Feb 22, 2027Primary completion: phase 3 study in NeoplasmsAstraZeneca · NCT05629234
  2. Aug 2, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05120349
  3. Oct 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05801029
  4. May 30, 2029Primary completion: phase 2 study in Lung NeoplasmsAstraZeneca · NCT07295821

TargetBeta

EGFR →read by rule
“A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07295821Lung Neoplasms · China2RecruitingAstraZenecaMay 30, 202960
NCT06194448Lung Neoplasms · United States, China, Israel and more2Active, not recruitingAstraZenecaJul 7, 202676
NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more2Active, not recruitingAstraZenecaOct 1, 202760
NCT05629234Neoplasms · China, France, Japan and more3Active, not recruitingAstraZenecaFeb 22, 202737
NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma · United States, Hong Kong, Italy and more2Active, not recruitingAstraZenecaNov 22, 2029188
NCT05546866Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingAstraZenecaJun 30, 202951
NCT05215951Lung Neoplasms · China2TerminatedAstraZenecaMar 9, 20234
NCT05120349Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3Active, not recruitingAstraZenecaAug 2, 2027390
NCT04816214Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Singapore3TerminatedNovartisDec 27, 20226
NCT04765059Carcinoma, Non-Small-Cell Lung · United States, China, Germany and more3Active, not recruitingAstraZenecaOct 28, 202498
NCT04606771Carcinoma, Non-Small-Cell Lung · United States, Argentina, India and more2Active, not recruitingAstraZenecaDec 21, 202230
NCT04351555Carcinoma, Non-Small-Cell Lung · United States, Austria, Brazil and more3Active, not recruitingAstraZenecaOct 15, 2024358
NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more2Active, not recruitingAstraZenecaMay 6, 2025247
NCT03853551Carcinoma, Non-Small-Cell Lung · India4CompletedAstraZenecaApr 15, 202060
NCT03521154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3Active, not recruitingAstraZenecaJan 5, 2024216
NCT03463525Carcinoma, Non-Small-Cell Lung · Sweden1CompletedAstraZenecaMar 19, 20204
NCT03239340Carcinoma, Non-Small-Cell Lung · United States, Italy, Korea, Republic of and more2CompletedAstraZenecaSep 19, 2023154
NCT02997501Lung Neoplasms · China3CompletedAstraZenecaOct 24, 2018256
NCT02923947Renal Insufficiency · France, Korea, Republic of, Spain1CompletedAstraZenecaSep 20, 201816
NCT02908750Carcinoma, Non-Small-Cell Lung · France, Korea, Republic of, Spain1CompletedAstraZenecaJul 31, 201724
NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more1CompletedEli LillyOct 19, 201729
NCT02529995Carcinoma · China1CompletedAstraZenecaJan 28, 201631
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaApr 11, 2022682
NCT02491944Neoplasms · United Kingdom1CompletedAstraZenecaAug 201527
NCT02474355Lung Neoplasms · Argentina, Australia, Austria and more3CompletedAstraZenecaApr 18, 20193,017
NCT02454933Locally Advanced or Metastatic EGFR T790M+ NSCLC · Canada, Korea, Republic of, Taiwan3CompletedAstraZenecaAug 21, 201729
NCT02442349Carcinoma, Non-Small-Cell Lung · Australia, China, South Korea2CompletedAstraZenecaMar 4, 2016171
NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more3Active, not recruitingEli LillyJan 23, 2019545
NCT02317016Carcinoma, Non-Small-Cell Lung · United States, France, Spain and more1CompletedAstraZenecaJul 11, 201544
NCT02228369Carcinoma, Non-Small-Cell Lung · United States, Australia, Korea, Republic of and more1CompletedAstraZenecaAug 19, 2017108
NCT02224053Neoplasms · United States1CompletedAstraZenecaJan 2015136
NCT02197247Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of, Netherlands and more1CompletedAstraZenecaJul 9, 201541
NCT02197234Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more1CompletedAstraZenecaApr 30, 201552
NCT02179671Carcinoma, Non-Small-Cell Lung · United States2CompletedAstraZenecaJun 11, 201632
NCT02157883Carcinoma, Non-Small-Cell Lung · United States, Belgium, Netherlands and more1CompletedAstraZenecaApr 3, 201539
NCT02163733Carcinoma, Non-Small-Cell Lung · France, Korea, Republic of, Spain and more1CompletedAstraZenecaMar 24, 201538
NCT02161770Neoplasms · United States, Belgium, France and more1CompletedAstraZenecaMay 16, 201730
NCT02143466Advanced Non Small Cell Lung Cancer · United States, Canada, Japan and more1Active, not recruitingAstraZenecaMar 4, 2020344
NCT02096679Healthy Volunteers · United Kingdom1CompletedAstraZenecaAug 20148
NCT02094261Carcinoma, Non-Small-Cell Lung · United States, Canada, Hong Kong and more2CompletedAstraZenecaMay 1, 2015210
NCT01951599Healthy Volunteers · United States1CompletedAstraZenecaJun 4, 201435
NCT01802632Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2CompletedAstraZenecaMay 1, 2015603

How it is read

Names in the registry

  • “Osimertinib”, 14 entries
  • “AZD9291”, 14 entries
  • “AZD9291 tablet dosing”, 5 entries
  • “AZD9291 Dosing”, 2 entries
  • “Part A - AZD9291 in combination with AZD6094”, 1 entry

Codes read as this program: AZD9291.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.